Selective Pyrimidine Derivatives Targeting Staphylococcus aureus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial compounds face challenges in selectively targeting Staphylococcus aureus without inducing resistance in other bacterial strains, and existing pyrimidine compounds lack specific use in treating bacterial infections.
Innovation Solution
Development of novel pyrimidine compounds of formula I, which include specific structural features such as various substituents and functional groups, that exhibit selective activity against Staphylococcus aureus, potentially minimizing resistance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad-spectrum antibacterial compounds are used to treat bacterial infections, then the treatment coverage is improved, but resistance development in bacteria occurs
Solution Approach 1:
The patent applies local quality by designing pyrimidine compounds with specific substituent patterns (Y groups at positions 2 and 6, specific R groups at positions 3 and 5) that create localized interactions with bacterial targets. This specificity allows the compound to selectively target S. aureus while sparing other bacteria, thus maintaining treatment coverage for the pathogen while avoiding broad resistance selection pressure.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of pyrimidine compounds through different substituents (Y = —CF3, —N(C1-6 alkyl)2, C3-6 cycloalkyl; various R groups including aryl, heteroaryl, alkyl with halo substitutions). These structural parameter modifications enable fine-tuning of bacterial selectivity and activity profile to achieve targeted therapy.
2Reliability
If selective antibacterial compounds are developed to target specific bacterial strains, then resistance development is minimized, but the treatment versatility is reduced
Solution Approach 1:
The patent achieves universality by creating a series of related pyrimidine compounds (formula I) that can be adjusted through substituent variation to target different bacterial strains or infections. The core pyrimidine structure with specific Y groups provides the selective mechanism against S. aureus, while the variable R groups (aryl, heteroaryl, alkyl with different substitutions) enable adaptation to different clinical scenarios, maintaining both selectivity and versatility.
3Ease of manufacture
If existing pyrimidine compounds are used for antibacterial purposes, then the compound availability is improved, but the selective activity against Staphylococcus aureus is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the pyrimidine compound into distinct functional segments: the core pyrimidine ring, the Y substituents at positions 2 and 6 (which provide selective activity against S. aureus), and the R groups at positions 3 and 5 (which can be varied for different properties). This modular structure allows the compound to maintain availability through known pyrimidine chemistry while achieving the required selective activity through specific segment configuration.
Data Source
AI summary
The present invention relates to novel compounds of formula I:or a pharmaceutically acceptable salt thereof, wherein the integers are as defined in the description.The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.